Skip to content

Clinical trials

Multiple Sclerosis, Relapsing-Remitting trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Sclerosis, Relapsing-Remitting Country / region: United States Clear all

228 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20025
200310
20044
20052
200610
200710
20085
20097
201012
20118
20128
201311
20149
201513
20168
201711
201813
201913
20205
202110
202210
202314
20248
202510
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed136
Terminated28
Recruiting18
Active, not recruiting17
Unknown status14
Withdrawn7
Not yet recruiting3
Suspended3
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Biogen29
Novartis Pharmaceuticals10
Johns Hopkins University8
Bayer7
Genzyme, a Sanofi Company7
Hoffmann-La Roche6
National Institute of Allergy and Infectious Diseases (NIAID)5
Shirley Ryan AbilityLab5
University of California, San Francisco5
EMD Serono4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Sclerosis, Relapsing-Remitting228
Multiple Sclerosis120
Multiple Sclerosis, Chronic Progressive32
Fatigue8
Recurrence7
Demyelinating Diseases6
Autoimmune Diseases4
Nervous System Diseases4
Autoimmune Diseases of the Nervous System3
Hypoxia3

Trials

Showing 1 to 25 of 228. Each trial links to its page on Pharma Observatory.

128 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.